Apr 25, 2016 | Compliance, Legal, and Malpractice, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Sales and Marketing
Legislation has been introduced that, if passed, would ensure health consumers have the opportunity to see and correct information held by data brokers
When it comes to patient privacy, pathologists and clinical laboratory managers may be spending more time addressing a growing issue with the patient data their labs create and store. Third-party data brokers want to position themselves to collect healthcare data at the source so can they de-identify it and sell it to interested parties.
Data brokers are commercial entities that collect, assemble, and/or maintain personal information about individuals. They also sell or provide third-party access to the information, explained the Congressional Research Service, a Legislative Branch Agency that provides policy and legal analysis to both House and Senate members and committees of the U.S. Congress, regardless of party affiliation.
Pharmaceutical companies, medical device manufacturers, and other businesses can purchase said data from various types of data brokers, such as information, analysis, and technology companies. The purchased data then can go on to guide industry investments or launch drug marketing campaigns. (more…)
Mar 30, 2016 | Compliance, Legal, and Malpractice, Digital Pathology, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory Pathology, Laboratory Testing
IBM Health’s data combined with Truven’s patient records will create an enormous big-data collection representing 300 million patient lives
If any pathologist or clinical laboratory manager still doubts the importance of healthcare big data, the multi-billion-dollar acquisition of Truven Health Analytics by IBM should put those doubts to rest.
Last month, IBM Corp. (NYSE:IBM) announced an agreement to acquire Truven Health Analytics, (Truven) for $2.6 billion. Truven is a provider of cloud-based healthcare, analytics, and insights and is based in Ann Arbor, Michigan. (more…)
Jun 20, 2012 | Coding, Billing, and Collections, Compliance, Legal, and Malpractice, Digital Pathology, Instruments & Equipment, Laboratory Hiring & Human Resources, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Sales and Marketing
Business Intelligence software now allows for real-time data capture, analysis and evaluation of medical laboratory operations
For clinical laboratories and anatomic pathology groups across the nation, the latest use of middleware is for business intelligence. This is a brand-new trend, as only first-mover and early adopter medical laboratories have acquired and currently use some type of middleware solution that delivers business intelligence.
One-by-one, laboratory informatics companies are crafting middleware products specifically designed to deliver business intelligence to their customers and clients. Business Intelligence (BI) is a computer-based approach to collecting and analyzing business data. A flurry of activity in the laboratory informatics sector reinforces the importance of health IT and healthcare analytics in an increasingly competitive medical laboratory testing market. (more…)
Jun 15, 2011 | Laboratory News, Laboratory Pathology
Watson is capable of assessing health data, including medical laboratory test results
When IBM’s Watson “supercomputer” squared off against human contestants on the Jeopardy game show last February, there certainly were some pathologists and clinical laboratory managers watching this “man versus machine” battle of knowledge. But those pathologists and medical lab managers did not realize that IBM intends for Watson to play a major role in helping physicians diagnose and treat disease.
IBM is designing Watson to use analytical algorithms to support how physicians assess information as they evaluate patients. In this role, it is likely that Watson will be fed laboratory test data and evidence-based medicine algorithms as part of the data it draws upon to help physicians more accurately diagnose disease and come up with appropriate treatment plans. (more…)
Oct 20, 2010 | Laboratory News, Laboratory Pathology
Company will develop solutions for new reimbursement models, evidence-based care, and supporting health service delivery needs
Earlier this fall, IBM Corporation (NYSE: IBM) announced plans to invest $100 million specifically to advance IBM capabilities in three key areas of healthcare informatics. That seemed like a big deal that might affect clinical pathology, since IBM is one of the information technology (IT) giants in the United States.
However, Dark Daily editors made a surprising discovery as they researched the news of IBM’s new $100 million healthcare IT investment initiative. IBM has a habit of making $100 million investments in recent years! It has learned that dropping a press release that announces a $100 million IT investment initiative generates plenty of press coverage.
(more…)
